Pharmaceutical intermediates

Cabozantinib S-malate Intermediates

3 pharmaceutical intermediates for Cabozantinib S-malate. Indication: Pancreatic neuroendocrine tumors; Renal cell carcinoma; Hepatocellular carcinoma; Thyroid cancer; Neuroendocrine carcinoma.

提交项目 All intermediates

About Cabozantinib S-malate

Originator: Exelixis Inc
Indication: Pancreatic neuroendocrine tumors; Renal cell carcinoma; Hepatocellular carcinoma; Thyroid cancer; Neuroendocrine carcinoma
Approved Date: 11/29/2012
DS/DP: 08/14/2026

Available intermediates

3 intermediates currently listed for Cabozantinib S-malate. Request specifications, documentation or a quotation for any item below.

Cabozantinib S-malate intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
4-Hydroxy-6,7-dimethoxyqunioline	13425-93-9	/	/
4-((6,7-Dimethoxyquinolin -4-yl)oxy)aniline	190728-25-7	/	/
1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid	849217-48-7	/	/

Other programs under C

Calcipotriol Calcitriol Camlipixant Canagliflozin Cangrelor Tetrasodium Capivasertib Capmatinib Hydrochloride Carfilzomib

Building toward Cabozantinib S-malate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →